Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Safety and Immunogenicity of Sequential Rotavirus Vaccine Schedules With RotaTeq® and Rotarix®
Brief Summary: Rotavirus, sometimes called the "stomach flu," is the most common cause of severe diarrhea in children. Vaccines can prevent many types of infections and work by causing the body to make proteins called antibodies that fight infection. For some vaccines, more than one vaccination is needed so that the body will make enough antibodies to fight infection. The vaccines (RotaTeq® or Rotarix® oral vaccines) given in this study are recommended for infants by the Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP). These vaccines require either 2 or 3 vaccinations to be effective. Healthy infants between 6 weeks and 14 weeks, 6 days of age at Visit 1 will participate for about 10-12 months. Study procedures include reaction assessment and blood sample.


Options:
A: Arm Label: Group 1, RotaTeq® x 3; Type: ACTIVE_COMPARATOR; Interventions: Biological: RotaTeq® | Arm Label: Group 5, Rotarix®, RotaTeq® x2; Type: EXPERIMENTAL; Interventions: Biological: Rotarix®, Biological: RotaTeq® | Arm Label: Group 4, Rotarix® x 2; Type: ACTIVE_COMPARATOR; Interventions: Biological: Rotarix® | Arm Label: Group 2, RotaTeq®, Rotarix® x 2; Type: EXPERIMENTAL; Interventions: Biological: Rotarix®, Biological: RotaTeq® | Arm Label: Group 3, RotaTeq® x 2, Rotarix®; Type: EXPERIMENTAL; Interventions: Biological: Rotarix®, Biological: RotaTeq® | Intervention Type: BIOLOGICAL; Name: Rotarix®; Assigned to Arm(s): Group 2, RotaTeq®, Rotarix® x 2, Group 3, RotaTeq® x 2, Rotarix®, Group 4, Rotarix® x 2, Group 5, Rotarix®, RotaTeq® x2 | Intervention Type: BIOLOGICAL; Name: RotaTeq®; Assigned to Arm(s): Group 1, RotaTeq® x 3, Group 2, RotaTeq®, Rotarix® x 2, Group 3, RotaTeq® x 2, Rotarix®, Group 5, Rotarix®, RotaTeq® x2
B: Arm Label: PLACEBO-ROTARIX-ROTARIX GROUP; Type: EXPERIMENTAL; Interventions: Biological: Rotarix™, Biological: Placebo | Arm Label: ROTARIX-PLACEBO-ROTARIX GROUP; Type: EXPERIMENTAL; Interventions: Biological: Rotarix™, Biological: Placebo | Arm Label: PLACEBO GROUP; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: Rotarix™; Assigned to Arm(s): PLACEBO-ROTARIX-ROTARIX GROUP, ROTARIX-PLACEBO-ROTARIX GROUP | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): PLACEBO GROUP, PLACEBO-ROTARIX-ROTARIX GROUP, ROTARIX-PLACEBO-ROTARIX GROUP
C: Arm Label: Vaccine Arm; Type: EXPERIMENTAL; Interventions: Biological: Live Attenuated Pentavalent (G1-G2-G3-G4-G9) Human X Bovine Reassortant Rotavirus Vaccine (BRV-PV) | Arm Label: Placebo group; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: BIOLOGICAL; Name: Live Attenuated Pentavalent (G1-G2-G3-G4-G9) Human X Bovine Reassortant Rotavirus Vaccine (BRV-PV); Assigned to Arm(s): Vaccine Arm | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo group
D: Intervention Type: BIOLOGICAL; Name: 2-dose oral live attenuated G1P[8] human rotavirus vaccine; Assigned to Arm(s): N/A

Answer: A